Tianda Pharmaceuticals (HKSE:00455) COGS-to-Revenue : 0.56 (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is Tianda Pharmaceuticals COGS-to-Revenue?

Tianda Pharmaceuticals's Cost of Goods Sold for the six months ended in Dec. 2023 was HK$128.2 Mil. Its Revenue for the six months ended in Dec. 2023 was HK$228.6 Mil.

Tianda Pharmaceuticals's COGS to Revenue for the six months ended in Dec. 2023 was 0.56.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Tianda Pharmaceuticals's Gross Margin % for the six months ended in Dec. 2023 was 43.93%.

Tianda Pharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for Tianda Pharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianda Pharmaceuticals COGS-to-Revenue Chart

Tianda Pharmaceuticals Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.20

0.27

0.45

0.53

0.52

Tianda Pharmaceuticals Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Jun23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															0.53	0.52	0.51	0.49	0.56

Tianda Pharmaceuticals COGS-to-Revenue Calculation

Tianda Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	276.557	/	532.089
	=	0.52

Tianda Pharmaceuticals's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	128.17	/	228.605
	=	0.56

Tianda Pharmaceuticals (HKSE:00455) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Tianda Pharmaceuticals's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	128.17 / 228.605
	=	43.93 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Tianda Pharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Tianda Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Tianda Pharmaceuticals (HKSE:00455) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianda Pharmaceuticals Ltd (HKSE:00455) » Definitions » COGS-to-Revenue

Traded in Other Exchanges

N/A

Address

CITIC Tower, No. 1 Tim Mei Avenue, Suites 2405-2410, 24th Floor, Central, Hong Kong, HKG

Website

https://www.tiandapharma.com

Tianda Pharmaceuticals Ltd is engaged in R&D, manufactures and sales of pharmaceutical, biotechnology and healthcare products. The group also engages in R&D of Chinese medicine and manufacture and sales of Chinese medicine products, and the provision of Chinese medical services. Its operating segments include Chinese medicine business; Medical and healthcare services; and Pharmaceuticals and medical technologies business. The company derives majority of the revenue from Pharmaceuticals and medical technologies business.

Executives

Tianda Group Limited	2101 Beneficial owner
Fang Wen Quan	2201 Interest of corporation controlled by you

Tianda Pharmaceuticals (HKSE:00455) Headlines

No Headlines